Pentagalloyl glucose inhibits TNF‐α‐activated CXCL1/GRO-α expression and induces apoptosis‐related genes in triple-negative breast cancer cells

• Published in: Scientific reports Vol. 11; no. 1; p. 5649
• Main Authors: Mendonca, Patricia, Alghamdi, Sumaih, Messeha, Samia, Soliman, Karam F. A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.03.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/436/2387; 631/67/1347; Apoptosis; Breast cancer; Cell growth; Cell proliferation; Chemotherapy; Drug resistance; Humanities and Social Sciences; Immune response; MAP kinase; mRNA; multidisciplinary; Science; Science (multidisciplinary); Signal transduction; Tumor microenvironment; Tumor necrosis factor-α; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-85090-z

In triple-negative breast cancer (TNBC), the tumor microenvironment is associated with increased proliferation, suppressing apoptotic mechanisms, an altered immune response, and drug resistance. The current investigation was designed to examine the natural compound pentagalloyl glucose (PGG) effects on TNF-α activated TNBC cell lines, MDA-MB-231 and MDA-MB-468. The results obtained showed that PGG reduced the expression of the cytokine GRO-α/CXCL1. PGG also inhibited IƙBKE and MAPK1 genes and the protein expression of IƙBKE and MAPK, indicating that GRO-α downregulation is possibly through NFƙB and MAPK signaling pathway. PGG also inhibited cell proliferation in both cell lines. Moreover, PGG induced apoptosis, modulating caspases, and TNF superfamily receptor genes. It also augmented mRNA of receptors DR4 and DR5 expression, which binds to TNF-related apoptosis-induced ligand, a potent and specific stimulator of apoptosis in tumors. Remarkably, PGG induced a 154-fold increase in TNF expression in MDA-MB-468 compared to a 14.6-fold increase in MDA-MB-231 cells. These findings indicate PGG anti-cancer ability in inhibiting tumor cell proliferation and GRO-α release and inducing apoptosis by increasing TNF and TNF family receptors' expression. Thus, PGG use may be recommended as an adjunct therapy for TNBC to increase chemotherapy effectiveness and prevent cancer progression.